个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Analysis of the clinical applicability of modified residual cancer burden system in evaluating the pathological response of breast cancer after neoadjuvant treatment

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP) ◇ 自然指数

作者：
Ma, Yanqi[1] * ; Liu, Yueping[1] ;
机构： [1]Hebei Med Univ, Hosp 4, Dept Pathol, Shijiazhuang, Hebei, Peoples R China
出处：
ISSN：

关键词： Neoadjuvant therapy Residual cancer burden Pathologic complete response Human epidermal growth factor receptor 2 Molecular type

语种：
外文
WOS：
中科院分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Hebei Med Univ, Hosp 4, Dept Pathol, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Ma Yanqi,Liu Yueping.Analysis of the clinical applicability of modified residual cancer burden system in evaluating the pathological response of breast cancer after neoadjuvant treatment[J].CANCER RESEARCH.2021,81(4):
APA：
Ma, Yanqi&Liu, Yueping.(2021).Analysis of the clinical applicability of modified residual cancer burden system in evaluating the pathological response of breast cancer after neoadjuvant treatment.CANCER RESEARCH,81,(4)
MLA：
Ma, Yanqi,et al."Analysis of the clinical applicability of modified residual cancer burden system in evaluating the pathological response of breast cancer after neoadjuvant treatment".CANCER RESEARCH 81..4(2021)

相关文献

[1]Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy [2]Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram [3]Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) [4]Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer [5]Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2. [6]Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy [7]More than 14 years' progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report [8]Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study [9]人表皮生长因子受体－2及雌激素受体与乳腺癌的关系 [10]Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号